首页 > 最新文献

Global health & medicine最新文献

英文 中文
HIV-1 protease inhibitors and mechanisms of HIV-1's resistance. HIV-1蛋白酶抑制剂和HIV-1耐药机制
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01073
Debananda Das

Current anti-HIV drugs have significantly improved the prognosis of HIV infected patients so much so that it is now considered a chronic disease, and adherence to medications keeps non-detectable amounts of the virus in the body. However, HIV is still able to generate drug resistance substitutions. Protease inhibitors (PIs) in combination with other classes of anti-HIV drugs constitute an important part of the anti-HIV drug regimen. This article discusses some of the common resistance substitutions against PIs, mechanistic insight on resistance, and potential new inhibitors that can show efficacy against current resistant variants.

目前的抗艾滋病毒药物已经显著改善了艾滋病毒感染者的预后,以至于它现在被认为是一种慢性疾病,坚持服用药物会使体内的病毒数量无法检测到。然而,艾滋病毒仍然能够产生耐药替代品。蛋白酶抑制剂(PIs)与其他类型的抗hiv药物联合使用是抗hiv药物方案的重要组成部分。本文讨论了一些针对pi的常见耐药替代品,耐药性的机制见解,以及可能对当前耐药变体有效的潜在新抑制剂。
{"title":"HIV-1 protease inhibitors and mechanisms of HIV-1's resistance.","authors":"Debananda Das","doi":"10.35772/ghm.2024.01073","DOIUrl":"10.35772/ghm.2024.01073","url":null,"abstract":"<p><p>Current anti-HIV drugs have significantly improved the prognosis of HIV infected patients so much so that it is now considered a chronic disease, and adherence to medications keeps non-detectable amounts of the virus in the body. However, HIV is still able to generate drug resistance substitutions. Protease inhibitors (PIs) in combination with other classes of anti-HIV drugs constitute an important part of the anti-HIV drug regimen. This article discusses some of the common resistance substitutions against PIs, mechanistic insight on resistance, and potential new inhibitors that can show efficacy against current resistant variants.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"357-362"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increase in the number of female doctors and the challenges that Japan's medical system must face. 女医生数量的增加和日本医疗系统必须面对的挑战。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01067
Shotaro Kinoshita, Taishiro Kishimoto

Japan has seen an increase in female physicians recently, yet it still lags behind other Organization for Economic Cooperation and Development (OECD) countries. A major barrier has been the historical discrimination against women in medical school admissions. In recent years, female enrolment in medical schools has risen, surpassing 40% in 2024, reflecting a broader societal shift. However, structural problems persist in the Japanese healthcare system. Although the number of doctors per capita is lower in Japan than in other countries, the number of patients is higher than in other countries, leading to overwork for doctors. As a result, only about one-third of female doctors in Japan are able to return to work after interrupting their careers to give birth or raise children. The maldistribution of physicians, both regionally and by specialty, exacerbates this issue. To sustain the rising number of female physicians, Japan must reform its medical system.

最近,日本的女医生有所增加,但仍落后于经济合作与发展组织(OECD)的其他国家。一个主要障碍是在医学院录取中对妇女的历史歧视。近年来,医学院的女性入学率有所上升,2024年超过40%,反映了更广泛的社会转变。然而,日本医疗体系的结构性问题依然存在。虽然日本的人均医生数量低于其他国家,但患者数量却高于其他国家,这导致了医生的过度劳累。因此,在日本,只有大约三分之一的女医生能够在中断职业生涯生育或抚养孩子后重返工作岗位。医生的分布不均,无论是地区还是专业,都加剧了这一问题。为了维持不断增长的女医生数量,日本必须改革其医疗体系。
{"title":"Increase in the number of female doctors and the challenges that Japan's medical system must face.","authors":"Shotaro Kinoshita, Taishiro Kishimoto","doi":"10.35772/ghm.2024.01067","DOIUrl":"10.35772/ghm.2024.01067","url":null,"abstract":"<p><p>Japan has seen an increase in female physicians recently, yet it still lags behind other Organization for Economic Cooperation and Development (OECD) countries. A major barrier has been the historical discrimination against women in medical school admissions. In recent years, female enrolment in medical schools has risen, surpassing 40% in 2024, reflecting a broader societal shift. However, structural problems persist in the Japanese healthcare system. Although the number of doctors per capita is lower in Japan than in other countries, the number of patients is higher than in other countries, leading to overwork for doctors. As a result, only about one-third of female doctors in Japan are able to return to work after interrupting their careers to give birth or raise children. The maldistribution of physicians, both regionally and by specialty, exacerbates this issue. To sustain the rising number of female physicians, Japan must reform its medical system.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"433-435"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of physical frailty and its associated factors among elderly patients undergoing hepatobiliary pancreatic surgery in China. 中国老年肝胆胰手术患者身体虚弱的患病率及其相关因素
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01089
Yi Deng, Rui Liao, Xiaofeng Hu, Keming Zhang, Jiali Zhu, Naomi Sato

Frailty is a geriatric syndrome characterized by a multisystem physiological decline, increased vulnerability to stressors, and adverse clinical outcomes. However, there is a knowledge gap regarding the association between frailty and its influencing factors. This study aimed to understand the current status of preoperative frailty in elderly patients with hepatobiliary pancreatic disease (HBP) and analyze debilitation-related factors. We enrolled 220 participants aged ≥ 65 years who underwent HBP surgery at two hospitals in China between December 2023 and February 2024. The physical frailty of elderly participants in communities with different characteristics was compared using Kruskal-Wallis and chi-square tests. Ordinal logistic regression analysis was used to analyze the factors influencing preoperative frailty. A total of 212 patients were included in the analysis based on the inclusion and exclusion criteria, with an overall prevalence of frailty at 53 (25%). Ordinal logistic regression analysis results showed that current smoking (odds ratio [OR] = 2.584, p = 0.006) was an independent risk factor for preoperative frailty in elderly participants with HBP. In contrast, exercise habits (OR = 0.323, p < 0.001), two or more multimorbidity statuses (OR = 0.495, p = 0.033), and independent status (OR = 0.216, p < 0.001) were protective factors. Our results suggest that having good exercise habits, not smoking, and independent status can prevent frailty progression in older adults who require HBP surgery. Interventions for frail elderly patients should be supported preoperatively by strengthening exercises to improve tolerance to surgery.

虚弱是一种老年综合征,其特征是多系统生理衰退,对压力源的易感性增加,以及不良的临床结果。然而,关于脆弱及其影响因素之间的关系,存在知识差距。本研究旨在了解老年肝胆胰疾病(HBP)患者术前虚弱的现状,并分析其相关因素。我们招募了220名年龄≥65岁的参与者,他们于2023年12月至2024年2月在中国的两家医院接受了HBP手术。采用Kruskal-Wallis检验和卡方检验比较不同特征社区老年参与者的身体虚弱程度。采用有序logistic回归分析术前虚弱的影响因素。根据纳入和排除标准,共有212例患者被纳入分析,总体虚弱患病率为53(25%)。有序logistic回归分析结果显示,当前吸烟(优势比[OR] = 2.584, p = 0.006)是老年高血压患者术前虚弱的独立危险因素。相反,运动习惯(OR = 0.323, p < 0.001)、两种及两种以上多病状态(OR = 0.495, p = 0.033)和独立状态(OR = 0.216, p < 0.001)是保护因素。我们的研究结果表明,良好的运动习惯、不吸烟和独立状态可以预防需要高血压手术的老年人的虚弱进展。对老年体弱患者术前应加强锻炼以提高手术耐受性。
{"title":"Prevalence of physical frailty and its associated factors among elderly patients undergoing hepatobiliary pancreatic surgery in China.","authors":"Yi Deng, Rui Liao, Xiaofeng Hu, Keming Zhang, Jiali Zhu, Naomi Sato","doi":"10.35772/ghm.2024.01089","DOIUrl":"10.35772/ghm.2024.01089","url":null,"abstract":"<p><p>Frailty is a geriatric syndrome characterized by a multisystem physiological decline, increased vulnerability to stressors, and adverse clinical outcomes. However, there is a knowledge gap regarding the association between frailty and its influencing factors. This study aimed to understand the current status of preoperative frailty in elderly patients with hepatobiliary pancreatic disease (HBP) and analyze debilitation-related factors. We enrolled 220 participants aged ≥ 65 years who underwent HBP surgery at two hospitals in China between December 2023 and February 2024. The physical frailty of elderly participants in communities with different characteristics was compared using Kruskal-Wallis and chi-square tests. Ordinal logistic regression analysis was used to analyze the factors influencing preoperative frailty. A total of 212 patients were included in the analysis based on the inclusion and exclusion criteria, with an overall prevalence of frailty at 53 (25%). Ordinal logistic regression analysis results showed that current smoking (odds ratio [OR] = 2.584, <i>p</i> = 0.006) was an independent risk factor for preoperative frailty in elderly participants with HBP. In contrast, exercise habits (OR = 0.323, <i>p</i> < 0.001), two or more multimorbidity statuses (OR = 0.495, <i>p</i> = 0.033), and independent status (OR = 0.216, <i>p</i> < 0.001) were protective factors. Our results suggest that having good exercise habits, not smoking, and independent status can prevent frailty progression in older adults who require HBP surgery. Interventions for frail elderly patients should be supported preoperatively by strengthening exercises to improve tolerance to surgery.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"394-403"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan. 日本过敏人群对mRNA - COVID-19疫苗的不良反应
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01053
Naoko Shoji, Suminobu Ito, Shuko Nojiri, Wataru Urasaki, Tamaki Nara, Atsushi Okuzawa, Morikuni Tobita

mRNA vaccines emerged as a new therapeutic modality during the COVID-19 pandemic. Individuals with allergies often experience anxiety about potential adverse reactions to these vaccines. This study aims to elucidate the relationship between adverse reactions and various allergies, asthma, or atopic disorders. Data from approximately 20,000 Japanese healthcare workers participating in a prospective cohort study were analyzed. The number of vaccinated individuals was 19,792 (first dose), with systemic reactions occurring in 35.8% after the first dose and 75.3% after the second dose. Participants with allergies were categorized into groups: food and/or drug allergies (n = 806), asthma and/or atopic disorders (n = 2,370), asthma (both past medical history [PMH] and present illness [PI]) (n = 1,983), and atopic disorders (PI) (n = 567). Most systemic reactions in those with food and/or drug allergies occurred within the first three days of vaccination. Logistic regression analysis showed that food and/or drug allergies, asthma (PMH and PI), and asthma and/or atopic disorders were significantly associated with systemic reactions (odds ratios [95% confidence interval]: 1.65 [1.43-1.91], 1.36 [1.23-1.49], and 1.32 [1.21-1.45], respectively, for the first dose). These findings suggest the risk of systemic reactions after COVID-19 vaccination in individuals with the specified allergies, potentially contributing to vaccine hesitancy. Medical professionals should clearly communicate the risks and benefits of vaccination to those with allergies to alleviate their concerns. Additionally, our study's data may be useful for making decisions whether or not to get vaccinated in those with allergies and inform the development of future mRNA vaccines.

mRNA疫苗在COVID-19大流行期间成为一种新的治疗方式。有过敏症的人通常会对这些疫苗的潜在不良反应感到焦虑。本研究旨在阐明不良反应与各种过敏、哮喘或特应性疾病之间的关系。研究人员分析了参与前瞻性队列研究的约20,000名日本医护人员的数据。接种人数为19,792人(首次接种),第一次接种后发生全身反应的人数为35.8%,第二次接种后发生全身反应的人数为75.3%。过敏症患者被分为食物和/或药物过敏(n = 806)、哮喘和/或特应性疾病(n = 2370)、哮喘(既往病史[PMH]和目前疾病[PI]) (n = 1983)和特应性疾病(n = 567)。大多数对食物和/或药物过敏的人的全身反应发生在接种疫苗的前三天。Logistic回归分析显示,食物和/或药物过敏、哮喘(PMH和PI)、哮喘和/或特应性疾病与全身反应显著相关(首次剂量的比值比[95%置信区间]分别为1.65[1.43-1.91]、1.36[1.23-1.49]和1.32[1.21-1.45])。这些发现表明,特定过敏症患者接种COVID-19疫苗后出现全身反应的风险,可能导致疫苗犹豫。医疗专业人员应明确告知过敏人群接种疫苗的风险和益处,以减轻他们的担忧。此外,我们的研究数据可能有助于决定过敏患者是否接种疫苗,并为未来mRNA疫苗的开发提供信息。
{"title":"Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan.","authors":"Naoko Shoji, Suminobu Ito, Shuko Nojiri, Wataru Urasaki, Tamaki Nara, Atsushi Okuzawa, Morikuni Tobita","doi":"10.35772/ghm.2024.01053","DOIUrl":"10.35772/ghm.2024.01053","url":null,"abstract":"<p><p>mRNA vaccines emerged as a new therapeutic modality during the COVID-19 pandemic. Individuals with allergies often experience anxiety about potential adverse reactions to these vaccines. This study aims to elucidate the relationship between adverse reactions and various allergies, asthma, or atopic disorders. Data from approximately 20,000 Japanese healthcare workers participating in a prospective cohort study were analyzed. The number of vaccinated individuals was 19,792 (first dose), with systemic reactions occurring in 35.8% after the first dose and 75.3% after the second dose. Participants with allergies were categorized into groups: food and/or drug allergies (<i>n</i> = 806), asthma and/or atopic disorders (<i>n</i> = 2,370), asthma (both past medical history [PMH] and present illness [PI]) (<i>n</i> = 1,983), and atopic disorders (PI) (<i>n</i> = 567). Most systemic reactions in those with food and/or drug allergies occurred within the first three days of vaccination. Logistic regression analysis showed that food and/or drug allergies, asthma (PMH and PI), and asthma and/or atopic disorders were significantly associated with systemic reactions (odds ratios [95% confidence interval]: 1.65 [1.43-1.91], 1.36 [1.23-1.49], and 1.32 [1.21-1.45], respectively, for the first dose). These findings suggest the risk of systemic reactions after COVID-19 vaccination in individuals with the specified allergies, potentially contributing to vaccine hesitancy. Medical professionals should clearly communicate the risks and benefits of vaccination to those with allergies to alleviate their concerns. Additionally, our study's data may be useful for making decisions whether or not to get vaccinated in those with allergies and inform the development of future mRNA vaccines.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"363-374"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-specific brain fluorodeoxyglucose positron emission tomography can detect the first effects of combination antiretroviral therapy in patient with HIV infection. 患者特异性脑氟脱氧葡萄糖正电子发射断层扫描可以检测艾滋病毒感染患者联合抗逆转录病毒治疗的首次效果。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01039
Miyako M Chikanishi, Junko Tanuma, Kenji Ishii, Muneyuki Sakata, Noritoshi Arai, Tomoyuki Noguchi, Kensuke Komatsu, Kimiteru Ito, Tetsuya Mizoue, Kazuo Kubota, Takeyuki Watadani, Hiroyuki Gatanaga, Shinichi Oka

Patient-specific brain fluorodeoxyglucose-positron emission tomography (FDG PET) can detect areas with abnormal FDG uptake in patients with human immunodeficiency virus (HIV) before and after combination antiretroviral therapy (cART). There were few reports about the same patients before and shortly after cART in FDG PET. It is well known that HIV-RNA levels decrease and cognitive impairments in patients with HIV tend to improve on neurocognitive performance tests 6 months after starting cART. We conducted a quantitative imaging analysis (FDG PET and voxel-based morphometry (VBM)) of eight patients at pre- and 6 months post- cART with neurocognitive performance tests. In terms of participant-specific changes between pre- and post-cART imaging, some area showed that the size of area with abnormal FDG uptake shrunk and became a nearly physiological level at 6 months post-cART. No apparent changes in VBM were observed in this short period. FDG PET might detect the first effect of cART.

患者特异性脑氟脱氧葡萄糖正电子发射断层扫描(FDG PET)可以检测人类免疫缺陷病毒(HIV)患者在联合抗逆转录病毒治疗(cART)前后FDG摄取异常的区域。在FDG PET中,很少有相同患者在cART之前和之后不久的报道。众所周知,在开始cART治疗6个月后,HIV- rna水平下降,HIV患者的认知障碍倾向于在神经认知性能测试中改善。我们对8名患者在cART术前和术后6个月进行了定量成像分析(FDG PET和基于体素的形态测定法(VBM)),并进行了神经认知表现测试。在cart前后的参与者特异性变化方面,部分区域显示FDG摄取异常区域的大小在cart后6个月缩小并接近生理水平。在这短时间内未观察到VBM的明显变化。FDG PET可以检测到cART的第一效应。
{"title":"Patient-specific brain fluorodeoxyglucose positron emission tomography can detect the first effects of combination antiretroviral therapy in patient with HIV infection.","authors":"Miyako M Chikanishi, Junko Tanuma, Kenji Ishii, Muneyuki Sakata, Noritoshi Arai, Tomoyuki Noguchi, Kensuke Komatsu, Kimiteru Ito, Tetsuya Mizoue, Kazuo Kubota, Takeyuki Watadani, Hiroyuki Gatanaga, Shinichi Oka","doi":"10.35772/ghm.2024.01039","DOIUrl":"10.35772/ghm.2024.01039","url":null,"abstract":"<p><p>Patient-specific brain fluorodeoxyglucose-positron emission tomography (FDG PET) can detect areas with abnormal FDG uptake in patients with human immunodeficiency virus (HIV) before and after combination antiretroviral therapy (cART). There were few reports about the same patients before and shortly after cART in FDG PET. It is well known that HIV-RNA levels decrease and cognitive impairments in patients with HIV tend to improve on neurocognitive performance tests 6 months after starting cART. We conducted a quantitative imaging analysis (FDG PET and voxel-based morphometry (VBM)) of eight patients at pre- and 6 months post- cART with neurocognitive performance tests. In terms of participant-specific changes between pre- and post-cART imaging, some area showed that the size of area with abnormal FDG uptake shrunk and became a nearly physiological level at 6 months post-cART. No apparent changes in VBM were observed in this short period. FDG PET might detect the first effect of cART.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"420-426"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of oral allylestrenol in women with recurrent spontaneous abortion: A retrospective clinical trial. 口服烯丙雌醇治疗复发性自然流产:一项回顾性临床试验。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01056
Jing Wang, Lisha Li, Jing Zhou, Xinyao Pan, Qing Qi, Hongmei Sun, Ming Liu, Ling Wang

Recurrent spontaneous abortion (RSA), defined as two or more clinically confirmed pregnancies that end before 20-24 weeks of gestation, encompasses both embryonic and fetal losses and is a significant clinical challenge. The aim of this study was to compare the efficacy of allylestrenol (AT) and progesterone in improving pregnancy outcomes in RSA. From June 2021 to June 2024, 480 participants were randomly assigned to an AT, Progesterone, or Control group. Key outcomes included early pregnancy rates, ongoing pregnancies with fetal heart activity, live birth rates after 24 weeks, and pregnancy loss before 24 weeks. Results indicated significantly higher pregnancy rates at 6-8 weeks in both the Allylestrenol (71.8%) and Progesterone groups (76.2%) compared to the Control group (57.5%). At 12 weeks, ongoing pregnancies with fetal heart activity were higher in the Allylestrenol (65%) and Progesterone groups (64%) versus the Control group (52.5%). Both treatment groups had higher live birth rates (60% and 60.6%) compared to the Control group (45%). Pregnancy loss before 24 weeks was lower in both treatment groups (31.8% and 33.1%) compared to the Control group (38.7%). No significant adverse reactions were observed, indicating good safety profiles for both treatments. These findings suggest that both treatments effectively improve pregnancy outcomes in cases of RSA with satisfactory safety, supporting their potential clinical use. However, further research is needed to explore their long-term effects and broader applicability in clinical settings.

复发性自然流产(RSA),定义为两次或两次以上临床证实的妊娠,在妊娠20-24周之前结束,包括胚胎和胎儿丢失,是一个重大的临床挑战。本研究的目的是比较烯丙雌醇(AT)和黄体酮在改善RSA妊娠结局方面的疗效。从2021年6月到2024年6月,480名参与者被随机分配到AT组、黄体酮组或对照组。主要结局包括早孕率、持续妊娠并伴有胎儿心脏活动、24周后的活产率和24周前的流产率。结果显示,与对照组(57.5%)相比,烯丙雌醇组(71.8%)和黄体酮组(76.2%)在6-8周的妊娠率均显著高于对照组(71.8%)。在妊娠12周时,烯丙雌醇组(65%)和黄体酮组(64%)的胎儿心脏活动高于对照组(52.5%)。两个治疗组的活产率(60%和60.6%)均高于对照组(45%)。与对照组(38.7%)相比,两个治疗组在24周前的妊娠损失(31.8%和33.1%)较低。没有观察到明显的不良反应,表明两种治疗方法的安全性都很好。这些发现表明,这两种治疗方法都有效地改善了RSA病例的妊娠结局,并具有令人满意的安全性,支持其潜在的临床应用。然而,需要进一步的研究来探索它们的长期效果和在临床环境中更广泛的适用性。
{"title":"Use of oral allylestrenol in women with recurrent spontaneous abortion: A retrospective clinical trial.","authors":"Jing Wang, Lisha Li, Jing Zhou, Xinyao Pan, Qing Qi, Hongmei Sun, Ming Liu, Ling Wang","doi":"10.35772/ghm.2024.01056","DOIUrl":"10.35772/ghm.2024.01056","url":null,"abstract":"<p><p>Recurrent spontaneous abortion (RSA), defined as two or more clinically confirmed pregnancies that end before 20-24 weeks of gestation, encompasses both embryonic and fetal losses and is a significant clinical challenge. The aim of this study was to compare the efficacy of allylestrenol (AT) and progesterone in improving pregnancy outcomes in RSA. From June 2021 to June 2024, 480 participants were randomly assigned to an AT, Progesterone, or Control group. Key outcomes included early pregnancy rates, ongoing pregnancies with fetal heart activity, live birth rates after 24 weeks, and pregnancy loss before 24 weeks. Results indicated significantly higher pregnancy rates at 6-8 weeks in both the Allylestrenol (71.8%) and Progesterone groups (76.2%) compared to the Control group (57.5%). At 12 weeks, ongoing pregnancies with fetal heart activity were higher in the Allylestrenol (65%) and Progesterone groups (64%) versus the Control group (52.5%). Both treatment groups had higher live birth rates (60% and 60.6%) compared to the Control group (45%). Pregnancy loss before 24 weeks was lower in both treatment groups (31.8% and 33.1%) compared to the Control group (38.7%). No significant adverse reactions were observed, indicating good safety profiles for both treatments. These findings suggest that both treatments effectively improve pregnancy outcomes in cases of RSA with satisfactory safety, supporting their potential clinical use. However, further research is needed to explore their long-term effects and broader applicability in clinical settings.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"427-432"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suicide attempt and self-harm among hospitalized children in Japan: A nationwide inpatient database study. 日本住院儿童的自杀企图和自残:一项全国住院患者数据库研究。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01052
Sachiko Kita, Kojiro Morita, Hideaki Watanabe, Nobuaki Michihata, Mayumi Morisaki, Noyuri Yamaji, Mari Ikeda, Hideo Yasunaga

This study aims to delineate the characteristics and clinical trajectories of suicide attempts and self-harm, and its gender and age differences among children. This nationwide retrospective cross-sectional study utilized data extracted from the Japanese Diagnosis Procedure Combination inpatient database spanning 2016 to 2017. Children aged 7-17 years admitted to acute care hospitals for suicide attempts and self-harm, were identified. Patient characteristics included age, gender, suicide method, and comorbid psychiatric disorders. Trajectory information included the duration of hospital stay, admission ward, psychiatric/psychological interventions, in-hospital mortality, and healthcare expenditure. Data analysis encompassed 1,704 children hospitalized for suicide attempts and self-harm. Among these, 49.4% were junior high school age, 69.0% for female, and 28.4% for underweight. Overdose emerged as the most prevalent method for suicide attempts and self-harm (49.9%). Notably, 66.0% did not receive a diagnosis of any mental illness, and 56.3% did not undergo psychiatric/psychological care during their hospitalization. Boys were more likely to use high-lethality suicide methods, such as hanging (p < 0.001), and die during hospitalization (p < 0.001). Conversely, girls were more likely to use low-lethality suicide methods, such as drug overdose (p < 0.001), and receive psychiatric/psychological intervention during hospitalization (p = 0.015). Children aged 7-12 years were more likely to use high-lethality suicide methods, such as hanging (p < 0.001), and be diagnosed with attention-deficit/hyperactivity disorder (p < 0.001) and less likely to receive psychiatric/psychological intervention (p = 0.005) compared with other age groups. These findings suggest the importance of developing gender and age sensitive health policies, systems, and interventions to prevent child suicide.

本研究旨在探讨儿童自杀企图和自残的特征、临床轨迹及其性别和年龄差异。这项全国性的回顾性横断面研究使用了从2016年至2017年日本诊断程序组合住院患者数据库中提取的数据。发现了因自杀和自残而被急症医院收治的7-17岁儿童。患者特征包括年龄、性别、自杀方式和共病精神障碍。轨迹信息包括住院时间、住院病房、精神病学/心理干预、住院死亡率和医疗保健支出。数据分析包括1,704名因自杀未遂和自残而住院的儿童。其中,初中生占49.4%,女性占69.0%,体重不足占28.4%。过量是自杀企图和自残最普遍的方法(49.9%)。值得注意的是,66.0%的人没有得到任何精神疾病的诊断,56.3%的人在住院期间没有接受精神/心理护理。男孩更有可能使用高致命性的自杀方式,如上吊(p < 0.001),并在住院期间死亡(p < 0.001)。相反,女孩更有可能使用低致死率的自杀方法,如药物过量(p < 0.001),并在住院期间接受精神病学/心理干预(p = 0.015)。与其他年龄组相比,7-12岁的儿童更倾向于使用高致命性的自杀方式,如上吊(p < 0.001),被诊断为注意力缺陷/多动障碍(p < 0.001),接受精神病学/心理干预的可能性更小(p = 0.005)。这些发现表明,制定对性别和年龄敏感的卫生政策、系统和干预措施对于预防儿童自杀具有重要意义。
{"title":"Suicide attempt and self-harm among hospitalized children in Japan: A nationwide inpatient database study.","authors":"Sachiko Kita, Kojiro Morita, Hideaki Watanabe, Nobuaki Michihata, Mayumi Morisaki, Noyuri Yamaji, Mari Ikeda, Hideo Yasunaga","doi":"10.35772/ghm.2024.01052","DOIUrl":"10.35772/ghm.2024.01052","url":null,"abstract":"<p><p>This study aims to delineate the characteristics and clinical trajectories of suicide attempts and self-harm, and its gender and age differences among children. This nationwide retrospective cross-sectional study utilized data extracted from the Japanese Diagnosis Procedure Combination inpatient database spanning 2016 to 2017. Children aged 7-17 years admitted to acute care hospitals for suicide attempts and self-harm, were identified. Patient characteristics included age, gender, suicide method, and comorbid psychiatric disorders. Trajectory information included the duration of hospital stay, admission ward, psychiatric/psychological interventions, in-hospital mortality, and healthcare expenditure. Data analysis encompassed 1,704 children hospitalized for suicide attempts and self-harm. Among these, 49.4% were junior high school age, 69.0% for female, and 28.4% for underweight. Overdose emerged as the most prevalent method for suicide attempts and self-harm (49.9%). Notably, 66.0% did not receive a diagnosis of any mental illness, and 56.3% did not undergo psychiatric/psychological care during their hospitalization. Boys were more likely to use high-lethality suicide methods, such as hanging (<i>p</i> < 0.001), and die during hospitalization (<i>p</i> < 0.001). Conversely, girls were more likely to use low-lethality suicide methods, such as drug overdose (<i>p</i> < 0.001), and receive psychiatric/psychological intervention during hospitalization (<i>p</i> = 0.015). Children aged 7-12 years were more likely to use high-lethality suicide methods, such as hanging (<i>p</i> < 0.001), and be diagnosed with attention-deficit/hyperactivity disorder (<i>p</i> < 0.001) and less likely to receive psychiatric/psychological intervention (<i>p</i> = 0.005) compared with other age groups. These findings suggest the importance of developing gender and age sensitive health policies, systems, and interventions to prevent child suicide.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"383-393"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging of unicentric hyaline-vascular variant of Castleman disease: Emphasis on perilesional fat stranding and fatty proliferation. Castleman病单中心透明血管变异型的影像学:强调病灶周围脂肪搁浅和脂肪增生。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01058
Sodai Hoshiai, Takeyuki Watadani, Shun Kagaya, Taishi Amano, Tomohiko Masumoto, Haruyasu Yamada, Izuru Matsuda, Ryota Matsuoka, Tetsuo Ushiku, Takahito Nakajima, Manabu Minami

The hyaline-vascular variant of Castleman disease (HVCD) is relatively uncommon and demonstrates no specific clinical or laboratory findings; therefore, its preoperative diagnosis warrants a radiological evaluation. This study aimed to review imaging findings of HVCD, focusing on perilesional fat stranding and fatty proliferation. Patients with a pathologically confirmed HVCD diagnosis who had undergone CT were recruited from five hospitals from January 2000 to March 2023. Three experienced radiologists assessed CT findings, including lesion location, lesion size, calcification, enhanced pattern, feeding vessel visualization, and arterial enhancement. Perilesional fat stranding, fatty proliferation, neighboring fascial thickening, and surrounding lymphadenopathy were the primary targets of analysis. Moreover, the intensities and apparent diffusion coefficient (ADC) values on MRI and the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography (PET) were evaluated. This study enrolled 43 patients (mean age 41.3 years ± 14.6 [standard deviation], 23 women). All lesions were well-defined round masses. Calcification and feeding vessels were detected in 21% (9/43) and 86% (36/43) of the patients, respectively. Perilesional fat stranding and fatty proliferation were observed in 44% (19/43) and 19% (8/43), respectively, with fatty proliferation detected only in retroperitoneal HVCD. Neighboring fascial thickening and surrounding lymphadenopathy were identified in 21% and 60%, respectively. The mean ADC value and SUVmax were 0.884 × 10-3 mm2/s and 5.0, respectively. Retroperitoneal HVCD cases with perilesional fatty proliferation demonstrated a higher visceral fat ratio than those without (p = 0.046). Perilesional fat stranding and fatty proliferation were new characteristics of HVCD, especially in retroperitoneal cases.

Castleman病的透明血管变异(HVCD)相对罕见,没有特定的临床或实验室发现;因此,其术前诊断需要放射学评估。本研究旨在回顾HVCD的影像学表现,重点关注病灶周围脂肪搁浅和脂肪增殖。从2000年1月至2023年3月从五家医院招募了病理证实的HVCD诊断并接受了CT检查的患者。三位经验丰富的放射科医生评估了CT表现,包括病变位置、病变大小、钙化、增强模式、供血血管显像和动脉增强。病灶周围脂肪搁浅、脂肪增生、邻近筋膜增厚和周围淋巴结病变是分析的主要目标。并对磁共振成像(MRI)的强度、表观扩散系数(ADC)值和18f -氟脱氧葡萄糖正电子发射断层扫描(PET)的最大标准化摄取值(SUVmax)进行了评价。本研究纳入43例患者(平均年龄41.3岁±14.6[标准差],女性23例)。所有病变均为清晰的圆形肿块。钙化和供血血管分别占21%(9/43)和86%(36/43)。44%(19/43)和19%(8/43)的HVCD患者存在病灶周围脂肪搁浅和脂肪增生,仅腹膜后HVCD患者存在脂肪增生。相邻筋膜增厚和周围淋巴结病变分别占21%和60%。平均ADC值为0.884 × 10-3 mm2/s, SUVmax为5.0。腹膜后HVCD伴病灶周围脂肪增生的患者内脏脂肪比不伴的患者高(p = 0.046)。病灶周围脂肪搁浅和脂肪增生是HVCD的新特征,特别是在腹膜后病例。
{"title":"Imaging of unicentric hyaline-vascular variant of Castleman disease: Emphasis on perilesional fat stranding and fatty proliferation.","authors":"Sodai Hoshiai, Takeyuki Watadani, Shun Kagaya, Taishi Amano, Tomohiko Masumoto, Haruyasu Yamada, Izuru Matsuda, Ryota Matsuoka, Tetsuo Ushiku, Takahito Nakajima, Manabu Minami","doi":"10.35772/ghm.2024.01058","DOIUrl":"10.35772/ghm.2024.01058","url":null,"abstract":"<p><p>The hyaline-vascular variant of Castleman disease (HVCD) is relatively uncommon and demonstrates no specific clinical or laboratory findings; therefore, its preoperative diagnosis warrants a radiological evaluation. This study aimed to review imaging findings of HVCD, focusing on perilesional fat stranding and fatty proliferation. Patients with a pathologically confirmed HVCD diagnosis who had undergone CT were recruited from five hospitals from January 2000 to March 2023. Three experienced radiologists assessed CT findings, including lesion location, lesion size, calcification, enhanced pattern, feeding vessel visualization, and arterial enhancement. Perilesional fat stranding, fatty proliferation, neighboring fascial thickening, and surrounding lymphadenopathy were the primary targets of analysis. Moreover, the intensities and apparent diffusion coefficient (ADC) values on MRI and the maximum standardized uptake value (SUVmax) on <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (PET) were evaluated. This study enrolled 43 patients (mean age 41.3 years ± 14.6 [standard deviation], 23 women). All lesions were well-defined round masses. Calcification and feeding vessels were detected in 21% (9/43) and 86% (36/43) of the patients, respectively. Perilesional fat stranding and fatty proliferation were observed in 44% (19/43) and 19% (8/43), respectively, with fatty proliferation detected only in retroperitoneal HVCD. Neighboring fascial thickening and surrounding lymphadenopathy were identified in 21% and 60%, respectively. The mean ADC value and SUVmax were 0.884 × 10<sup>-3</sup> mm<sup>2</sup>/s and 5.0, respectively. Retroperitoneal HVCD cases with perilesional fatty proliferation demonstrated a higher visceral fat ratio than those without (<i>p</i> = 0.046). Perilesional fat stranding and fatty proliferation were new characteristics of HVCD, especially in retroperitoneal cases.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"375-382"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis. 基线较高的FIB-4指数可预测社区病毒性肝炎队列中肝癌的发展。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01008
Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki, Kouki Nio, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Junko Tanaka, Shuichi Kaneko, Taro Yamashita

Hepatitis B and C (HBV and HCV) testing has been performed in Japan since 2002 and is subsidized by central and prefectural governments. A follow-up program for HBV- or HCV-infected persons was started at that time in Ishikawa Prefecture. This study analyzed the long-term follow-up data from this program. In total, 1029 participants in the Ishikawa Hepatitis Follow-up Program (HBV-infected, n = 535; HCV-infected, n = 494) were enrolled. Clinical data between the first visit and the most recent visit by March 2019 were collected. In the HBV-infected group, 384 persons (71.8%) were asymptomatic carriers, 133 (24.9%) developed chronic hepatitis, 15 (2.8%) developed compensated liver cirrhosis, and 3 (0.6%) developed decompensated liver cirrhosis. Ninety (16.8%) were treated with nucleotide/nucleoside analogs. Sixteen (3.0%) developed liver cancer. In the HCV-infected group, 427 persons (86.4%) developed chronic hepatitis, 46 (9.3%) developed compensated liver cirrhosis, and 21 (4.3%) developed decompensated liver cirrhosis. Forty-eight (9.7%) developed liver cancer. Three hundred and seventy-eight (76.5%) received antiviral therapy (a direct-acting antiviral in 166, interferon-based treatment followed by a direct-acting antiviral in 73, and interferon-based treatment in 139). The subsidy system was used by 270 persons (71.4%). Sustained virological response was confirmed in 340 persons (68.8%). A higher FIB-4 index at the first visit was a significant risk factor for liver cancer in HBV-infected and HCV-infected persons. The Ishikawa Hepatitis Follow-up Program has revealed the clinical course of HBV and HCV infection in community-dwelling individuals. The results will be used for micro-elimination at a prefectural level.

自2002年以来,日本开展了乙型和丙型肝炎(HBV和HCV)检测,并由中央和地方政府提供补贴。当时在石川县开始了一项针对HBV或hcv感染者的随访计划。本研究分析了该项目的长期随访数据。石川肝炎随访项目共纳入1029名参与者(hbv感染者,n = 535;纳入hcv感染者(n = 494)。收集到2019年3月第一次访问和最近一次访问之间的临床数据。在hbv感染组中,384人(71.8%)为无症状携带者,133人(24.9%)为慢性肝炎,15人(2.8%)为代偿性肝硬化,3人(0.6%)为失代偿性肝硬化。核苷酸/核苷类似物处理90例(16.8%)。16例(3.0%)发生肝癌。在hcv感染组中,427人(86.4%)发生慢性肝炎,46人(9.3%)发生代偿性肝硬化,21人(4.3%)发生失代偿性肝硬化。48人(9.7%)患肝癌。378人(76.5%)接受抗病毒治疗(166人接受直接作用抗病毒治疗,73人接受直接作用抗病毒治疗,139人接受干扰素治疗)。使用补贴制度的有270人(71.4%)。340人(68.8%)确认有持续的病毒学应答。首次就诊时较高的FIB-4指数是乙肝病毒感染者和丙型肝炎病毒感染者发生肝癌的重要危险因素。石川肝炎随访项目揭示了社区居民HBV和HCV感染的临床病程。结果将用于地级的微消除。
{"title":"Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis.","authors":"Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki, Kouki Nio, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Junko Tanaka, Shuichi Kaneko, Taro Yamashita","doi":"10.35772/ghm.2024.01008","DOIUrl":"10.35772/ghm.2024.01008","url":null,"abstract":"<p><p>Hepatitis B and C (HBV and HCV) testing has been performed in Japan since 2002 and is subsidized by central and prefectural governments. A follow-up program for HBV- or HCV-infected persons was started at that time in Ishikawa Prefecture. This study analyzed the long-term follow-up data from this program. In total, 1029 participants in the Ishikawa Hepatitis Follow-up Program (HBV-infected, <i>n</i> = 535; HCV-infected, <i>n</i> = 494) were enrolled. Clinical data between the first visit and the most recent visit by March 2019 were collected. In the HBV-infected group, 384 persons (71.8%) were asymptomatic carriers, 133 (24.9%) developed chronic hepatitis, 15 (2.8%) developed compensated liver cirrhosis, and 3 (0.6%) developed decompensated liver cirrhosis. Ninety (16.8%) were treated with nucleotide/nucleoside analogs. Sixteen (3.0%) developed liver cancer. In the HCV-infected group, 427 persons (86.4%) developed chronic hepatitis, 46 (9.3%) developed compensated liver cirrhosis, and 21 (4.3%) developed decompensated liver cirrhosis. Forty-eight (9.7%) developed liver cancer. Three hundred and seventy-eight (76.5%) received antiviral therapy (a direct-acting antiviral in 166, interferon-based treatment followed by a direct-acting antiviral in 73, and interferon-based treatment in 139). The subsidy system was used by 270 persons (71.4%). Sustained virological response was confirmed in 340 persons (68.8%). A higher FIB-4 index at the first visit was a significant risk factor for liver cancer in HBV-infected and HCV-infected persons. The Ishikawa Hepatitis Follow-up Program has revealed the clinical course of HBV and HCV infection in community-dwelling individuals. The results will be used for micro-elimination at a prefectural level.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"404-415"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of recent changes in treatment options for patients with hepatocellular carcinoma using data from a highly comprehensive Japanese national database: Impact of advances in systemic therapy and minimally invasive surgery. 利用高度综合的日本国家数据库的数据分析肝细胞癌患者治疗方案的最新变化:全身治疗和微创手术进展的影响。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01061
Takashi Kokudo, Yasuhide Yamada, Takehiro Sugiyama, Rei Goto, Norihiro Kokudo

In 2011, the Ministry of Health, Labour and Welfare started providing data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) for research purposes. The NDB is an exhaustive and valuable database for health policymaking and research. It provides an accurate and most recent visualization of the burden of hepatocellular carcinoma (HCC) in Japan. In this study, we analyzed the trend in HCC treatments using data from the NDB. The NDB data were retrospectively analyzed to calculate the number of patients who were diagnosed with HCC (International Classification of Diseases, version 10 code of C22.0) and underwent treatment from fiscal year (FY) 2016 to 2020. We observed the following trends in HCC treatments during the past 5 years: a slight increase in the number of liver resection (LR) cases (+5.4%), a decrease in the number of radiofrequency ablation cases (-15.2%), and a considerable decrease in the number of transarterial chemoembolization/transarterial embolization cases (-38.2%). However, the number of patients who received systemic therapy dramatically increased from 471 in FY 2016 to 1,584 in FY 2020 (+236%). Among LR cases, there was a remarkable increase in the number of laparoscopic procedures from 1,227 in FY 2016 to 2,057 in FY 2020 (+67.6%). This analysis of a national highly comprehensive database revealed a very recent visualization of HCC management in Japan, wherein the impact of recent advances in systemic therapy and minimally invasive surgery was prominent.

2011年,厚生劳动省开始提供日本国家健康保险索赔和特定健康检查数据库(NDB)的数据,用于研究目的。新开发银行是一个详尽而有价值的卫生政策制定和研究数据库。它提供了日本肝细胞癌(HCC)负担的准确和最新的可视化。在这项研究中,我们使用NDB的数据分析了HCC治疗的趋势。回顾性分析NDB数据,计算2016 - 2020财年诊断为HCC (International Classification of Diseases, version 10 code of C22.0)并接受治疗的患者数量。我们观察到在过去5年中HCC治疗的以下趋势:肝切除术(LR)病例数量略有增加(+5.4%),射频消融病例数量减少(-15.2%),经动脉化疗栓塞/经动脉栓塞病例数量大幅减少(-38.2%)。然而,接受全身治疗的患者数量从2016财年的471例急剧增加到2020财年的1584例(+236%)。在LR病例中,腹腔镜手术的数量从2016财年的1227例显著增加到2020财年的2057例(+67.6%)。通过对一个全国性的综合性数据库的分析,揭示了最近日本HCC治疗的可视化,其中系统性治疗和微创手术的最新进展的影响是突出的。
{"title":"Analysis of recent changes in treatment options for patients with hepatocellular carcinoma using data from a highly comprehensive Japanese national database: Impact of advances in systemic therapy and minimally invasive surgery.","authors":"Takashi Kokudo, Yasuhide Yamada, Takehiro Sugiyama, Rei Goto, Norihiro Kokudo","doi":"10.35772/ghm.2024.01061","DOIUrl":"10.35772/ghm.2024.01061","url":null,"abstract":"<p><p>In 2011, the Ministry of Health, Labour and Welfare started providing data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) for research purposes. The NDB is an exhaustive and valuable database for health policymaking and research. It provides an accurate and most recent visualization of the burden of hepatocellular carcinoma (HCC) in Japan. In this study, we analyzed the trend in HCC treatments using data from the NDB. The NDB data were retrospectively analyzed to calculate the number of patients who were diagnosed with HCC (International Classification of Diseases, version 10 code of C22.0) and underwent treatment from fiscal year (FY) 2016 to 2020. We observed the following trends in HCC treatments during the past 5 years: a slight increase in the number of liver resection (LR) cases (+5.4%), a decrease in the number of radiofrequency ablation cases (-15.2%), and a considerable decrease in the number of transarterial chemoembolization/transarterial embolization cases (-38.2%). However, the number of patients who received systemic therapy dramatically increased from 471 in FY 2016 to 1,584 in FY 2020 (+236%). Among LR cases, there was a remarkable increase in the number of laparoscopic procedures from 1,227 in FY 2016 to 2,057 in FY 2020 (+67.6%). This analysis of a national highly comprehensive database revealed a very recent visualization of HCC management in Japan, wherein the impact of recent advances in systemic therapy and minimally invasive surgery was prominent.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"416-419"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Global health & medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1